ContraVir Pharmaceuticals Inc Stock OTC Bulletin Board
Equities
US21234W1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
05-21 | Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 14.05M 19.22M |
---|---|---|---|---|---|
Net income 2022 | -42M -57.43M | Net income 2023 | -48M -65.64M | EV / Sales 2022 | - |
Net cash position 2022 | 51.14M 69.92M | Net cash position 2023 | 14.58M 19.93M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.5
x | P/E ratio 2023 |
-0.26
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.28% |
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 15-12-31 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-02 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 13-05-14 |
Timothy Block
BRD | Director/Board Member | 69 | 13-11-25 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 22-06-26 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+24.16% | 27.87B | |
-17.74% | 20.95B | |
-14.78% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |